Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.
|
14
Sep |
Medtronic Recognizes Recipient Of World Journal Of Surgery “Best Of 2008″ AwardCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
Medtronic (NYSE: MDT) today recognized Henning Dralle, M.D., Professor at the University of Halle-Wittenberg in Halle, Germany, who received the World Journal of Surgery award for Best Paper of 2008. Professor Dralle received the award as lead author for the paper, “Intraoperative Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery,” published in the Feb. 2008 issue of WJS, on Sunday, Sept. 6 at the annual International Surgical Week conference in Adelaide, Australia.
|
1
Sep |
TransEnterix Announces Positive First-in-Man Results With New Laparoscopic Surgical PlatformCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
Officials with TransEnterix announce that surgeons from the United States and Paraguay have successfully performed first-in-man studies of its revolutionary single-incision, single-port, four-channel laparoscopic surgical platform called the SPIDER™ System. The SPIDER System - short for Single Port Instrument Delivery Extended Reach - allows surgeons to perform minimally invasive abdominal surgeries entirely through the umbilicus, leaving no visible scar.
|
22
Jul |
Candela Receives Registration Approval To Market The Alex TriVantage Laser In BrazilCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
Candela Corporation (NASDAQ:CLZR) announced that it has received registration approval from the Brazilian National Health Surveillance Agency (ANVISA) to market the Candela Alex TriVantage® multi-wavelength, q-switched laser system in Brazil. “Until now, providing high quality and effective treatment for pigmented lesions and multi-color tattoos meant that Brazilian doctors needed to own at least two different lasers.
|
10
Jul |
BioElectronics Prepares For General Surgical Recovery FDA 510(k) Premarketing Application SubmissionCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced the Company is currently preparing an application for 510(k) premarket notification for submission to the Food and Drug Administration (FDA) for general surgical recovery. The filing will request an indication for the adjunct of use in palliative treatment of postoperative edema and pain in superficial soft tissue.
|
22
Jun |
London Surgeon Pioneering Scarless Abdominal Surgery Using Belly ButtonCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
A London surgeon is pioneering a new way to remove abdominal organs through the belly button using an approach called single incision laparoscopic surgery (SILS) which requires only a 10 mm cut in the navel to allow entry of a camera and all the surgical instruments and through which organs like the appendix and gall bladder can be removed.
|
4
Dec |
BioElectronics Announces Positive Clinical Results - Rapid Recovery Breast Augmentation StudyCategory: Cosmetic Medicine / Plastic Surgery | Leave a Comment |
BioElectronics Corp. (Pink Sheets:BIEL), the maker of ActiPatch™, the drug-free, anti-inflammatory patch, with an embedded, battery-operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced results from an important clinical study designed to determine the benefits of pulsed electromagnetic therapy using ActiPatch topical patch devices.